Oramed Pharmaceuticals Inc.
ORMP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001176309
No open-market purchases or sales by Oramed Pharmaceuticals Inc. insiders were filed in the last 90 days; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Oramed Pharmaceuticals Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 44 | 75 | +31 |
| Shares | 1.24M | 3.84M | +2.61M (+210.9%) |
| Value | $12.6M | $51.4M | +$38.9M (+309.5%) |
New holders (39)
Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (8)
Institutions that held Oramed Pharmaceuticals Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| ExodusPoint Capital Management, LP | 52,486 | $533.0K |
| Ameriprise Financial Inc | 11,972 | $122.0K |
| Marshall Wace, LLP | 11,563 | $117.0K |
| RMR Wealth Builders | 2,300 | $23.0K |
| Optimum Investment Advisors | 2,000 | $20.0K |
| Sowell Financial Services LLC | 1,757 | $19.0K |
| Bank of Montreal | 1,600 | $16.0K |
| Alpha DNA Investment Management LLC | 386 | $3.00K |